.INVESTIGATION HIGHLIGHT.16 Oct 2024.
In the NIAGARA litigation, the addition of perioperative durvalumab to typical treatment for muscle-invasive bladder cancer cells boosted event-free as well as on the whole survival, noting a brand-new treatment alternative for this health condition.